精准诊断试剂和智能设备
Search documents
仁度生物: 2025年半年度募集资金存放与实际使用情况的专项报告
Zheng Quan Zhi Xing· 2025-08-29 17:57
Fundraising Overview - The company raised a total of RMB 726.5 million by issuing 10 million shares at RMB 72.65 each, with a net amount of RMB 652.76 million after deducting issuance costs of RMB 73.74 million [1][2] - As of the report date, all raised funds have been received and verified by an accounting firm [2] Fund Utilization and Balance - Cumulative usage of the raised funds reached RMB 283.99 million, with RMB 31.16 million used in the first half of 2025 [2][6] - The company has RMB 380 million temporarily idle for cash management, with a remaining balance of RMB 18.24 million in the fundraising account [2][6] Fund Management System - The company established a fundraising management system to ensure the safety and efficiency of fund usage, complying with relevant laws and regulations [2][3] - A tripartite supervision agreement was signed with a bank and a sponsor to ensure strict approval for fund usage [3] Cash Management of Idle Funds - The company approved the use of up to RMB 430 million of temporarily idle funds for cash management, investing in safe and liquid financial products [4][5] - The report details various structured deposits and their expected returns, indicating a focus on capital preservation [5][6] Compliance and Reporting - The company has adhered to disclosure requirements, ensuring timely and accurate reporting of fundraising and usage status, with no violations noted [6][7]